Fujirebio
Tracked across 4 events · 75 articles · First seen Apr 14, 2026 · Last active Aug 24, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Fujirebio is a key player in the CLIA market, contributing significantly to market advancements with diverse product offerings and strategies.
Jun 05, 2026 · 6 articles
Business
Impact: Formed partnership with Agappe to develop diagnostics.
Jul 08, 2026 · 6 articles
Tech
Impact: Manufactures the FDA-cleared Lumipulse G pTau217 test; potential commercial beneficiary.
Jul 15, 2026 · 56 articles
Regulatory
Impact: Fujirebio's Lumipulse was the first FDA-cleared Alzheimer's blood test, but now faces increased competition from the Roche/Lilly test.
Aug 24, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Fujirebio live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard